Coherus Biosciences Inc  

(Public, NASDAQ:CHRS)   Watch this stock  
Find more results for CHRS
35.08
+1.36 (4.03%)
Jul 31 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 33.56 - 35.60
52 week 12.27 - 38.10
Open 33.56
Vol / Avg. 147,150.00/406,337.00
Mkt cap 1.33B
P/E     -
Div/yield     -
EPS -5.79
Shares 37.84M
Beta     -
Inst. own 38%
Aug 10, 2015
Q2 2015 Coherus BioSciences Inc Earnings Call - 4:30PM EDT - Add to calendar
Aug 10, 2015
Q2 2015 Coherus BioSciences Inc Earnings Release - 4:00PM EDT - Add to calendar
Jun 3, 2015
Coherus Biosciences Inc at Jefferies 2015 Global Healthcare Conference - Webcast
May 11, 2015
Q1 2015 Coherus BioSciences Inc Earnings Call - Webcast
May 11, 2015
Q1 2015 Coherus BioSciences Inc Earnings Release
May 7, 2015
Coherus BioSciences Inc at Deutsche Bank Health Care Conference - Webcast
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '15) 2014
Net profit margin -702.91% -280.26%
Operating margin -632.50% -207.94%
EBITD margin - -205.77%
Return on average assets -96.25% -74.30%
Return on average equity -311.28% -
Employees 66 -
CDP Score - -

Address

201 Redwood Shores Pkwy Ste 200
REDWOOD CITY, CA 94065-1181
United States - Map
+1-650-6493530 (Phone)
+1-302-6555049 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Coherus BioSciences, Inc. is a late-stage clinical biologics platform company focused on the global biosimilar market. The Company's clinical-stage pipeline consists of two anti-inflammatory agents targeting tumor necrosis factor (TNF), and a long-acting form of granulocyte colony-stimulating factor (G-CSF). The Company's product pipeline includes anti-TNF product candidate, CHS-0214, an etanercept (Enbrel) biosimilar candidate which is in Phase III clinical trials, and anti-TNF product candidate, CHS-1420, an adalimumab (Humira) biosimilar candidate which is in Phase III clinical trials. The Company also offers G-CSF product candidate, CHS-1701, a pegfilgrastim (Neulasta) biosimilar which has completed a Phase I study.

Officers and directors

Dennis M. Lanfear Chairman of the Board, President, Chief Executive Officer
Age: 59
Bio & Compensation  - Reuters
Jean-Frederic Viret Ph.D. Chief Financial Officer
Age: 49
Bio & Compensation  - Reuters
Peter K. Watler Chief Technology Officer
Age: 53
Bio & Compensation  - Reuters
Alan C. Herman Ph.D. Chief Scientific Officer
Age: 67
Bio & Compensation  - Reuters
Barbara K. Finck M.D. Chief Medical Officer
Age: 67
Bio & Compensation  - Reuters
Christos Richards Director
Age: 57
Bio & Compensation  - Reuters
August J. Troendle M.D. Director
Age: 58
Bio & Compensation  - Reuters
James I. Healy M.D., Ph.D. Independent Director
Age: 50
Bio & Compensation  - Reuters
V. Bryan Lawlis Jr., Ph.D. Independent Director
Age: 63
Bio & Compensation  - Reuters
Ali J. Satvat Independent Director
Age: 37
Bio & Compensation  - Reuters